Comparison
While LL-37 acts as a broad-spectrum antimicrobial and immunomodulatory peptide involved in host defense and wound repair, but can also promote inflammation and cancer cell proliferation in some contexts5215, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.
While LL-37 works as a cationic amphipathic 37-amino-acid cathelicidin peptide generated from hCAP18 that disrupts microbial membranes and modulates innate immunity, including chemotaxis, cytokine induction, and NET formation521586, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.
LL-37 is 37 amino acids long, whereas Tirzepatide is longer as it has a length of 39 amino acids. LL-37 is made up of a sequence of Leucine, Leucine, Glycine, Aspartic acid, Phenylalanine, Phenylalanine, Arginine, Lysine, Serine, Lysine, Glutamic acid, Lysine, Isoleucine, Glycine, Lysine, Glutamic acid, Phenylalanine, Lysine, Arginine, Isoleucine, Valine, Glutamine, Arginine, Isoleucine, Lysine, Aspartic acid, Phenylalanine, Leucine, Arginine, Asparagine, Leucine, Valine, Proline, Arginine, Threonine, Glutamic acid, Serine. Tirzepatide is made up of a sequence of sequence data not available in the current dataset.
LL-37
CAMP
Tirzepatide
Not assigned in the current dataset.